Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints

被引:15
作者
Capra, WB [1 ]
机构
[1] Chiron Corp, Dept Biostat & Clin Data Management, Emeryville, CA 94608 USA
来源
CONTROLLED CLINICAL TRIALS | 2004年 / 25卷 / 02期
关键词
discontinuation trial; classic randomized trial; phase II trials; simulations; hazard ratio; Weibull distribution;
D O I
10.1016/j.cct.2003.11.005
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The discontinuation design has been proposed as an alternative to the classic randomized design for evaluating the effect of an experimental agent on time-to-disease progression and survival duration. With this design, all enrolled patients are treated with an experimental agent for a fixed course of therapy. Those patients with progressive disease at or before the end of this fixed period are removed from trial while those with stable disease or better are randomized to continued treatment with the experimental agent or standard of care. Simulations presented in this paper demonstrate that for realistic situations, the loss in information cm patients enrolled but not randomized in the discontinuation design is of sufficient magnitude that it is underpowered as compared to the classic design of randomizing all enrolled subjects. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 7 条
  • [1] Group sequential designs for Phase II trials with historical controls
    Chang, MN
    Shuster, JJ
    Kepner, JL
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (04): : 353 - 364
  • [2] FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P20
  • [3] RANDOMIZED DISCONTINUATION TRIALS - UTILITY AND EFFICIENCY
    KOPEC, JA
    ABRAHAMOWICZ, M
    ESDAILE, JM
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (09) : 959 - 971
  • [4] Threats to the validity of clinical trials employing enrichment strategies for sample selection
    Leber, PD
    Davis, CS
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (02): : 178 - 187
  • [5] Randomized discontinuation design: Application to cytostatic antineoplastic agents
    Rosner, GL
    Stadler, W
    Ratain, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4478 - 4484
  • [6] A DESIGN FOR PHASE-II TESTING OF ANTICANCER AGENTS WITHIN A PHASE-III CLINICAL-TRIAL
    SCHAID, DJ
    INGLE, JN
    WIEAND, S
    AHMANN, DL
    [J]. CONTROLLED CLINICAL TRIALS, 1988, 9 (02): : 107 - 118
  • [7] OPTIMAL 2-STAGE DESIGNS FOR PHASE-II CLINICAL-TRIALS
    SIMON, R
    [J]. CONTROLLED CLINICAL TRIALS, 1989, 10 (01): : 1 - 10